Avage Related Published Studies
Well-designed clinical trials related to Avage (Tazarotene)
Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. [2010.05]
Comparative efficacy and safety results of two topical combination acne regimens. [2009.07]
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. [2007.12.01]
Tazarotene 0.1 percent cream plus clindamycin 1 percent gel versus tretinoin 0.025 percent gel plus clindamycin 1 percent gel in the treatment of facial acne vulgaris. [2007.07.13]
Tolerability comparison of adapalene gel, 0.3% versus tazarotene cream, 0.05% in subjects with healthy skin. [2007.06]
Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study. [2007.01]
Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study. [2006.09]
[Inhibition of promyelocytic leukemia gene by tazarotene in hyperproliferative epidermis of psoriasis] [2006.08]
Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. [2006.05]
Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. [2006.03]
Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. [2006.01]
Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. [2005.03]
A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage. [2005.02]
Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis. [2005]
Histological effects of tazarotene 0.1% cream vs. vehicle on photodamaged skin: a 6-month, multicentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin. [2004.12]
Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study. [2004.06]
Tazarotene 0.1% cream for the treatment of photodamage. [2004.04]
Cumulative irritation comparison of adapalene gel and solution with 2 tazarotene gels and 3 tretinoin formulations. [2003.07]
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. [2003.05]
Pharmacokinetics of tazarotene cream 0.1% after a single dose and after repeat topical applications at clinical or exaggerated application rates in patients with acne vulgaris or photodamaged skin. [2003]
Oral lichen planus: a preliminary clinical study on treatment with tazarotene. [2002.11]
Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial. [2002.11]
A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. [2002.10]
Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. [2002.04]
A clinical evaluation of tazarotene 0.1% gel, with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. [2002.03]
A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. [2002.02]
Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. [2002.02]
Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. [2002.02]
Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. [2001.12]
Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. [2001.11]
A pilot study to determine the effect of tazarotene gel 0.1% on steroid-induced epidermal atrophy. [2001.07]
Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. [2001.06]
Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis. [2000.12]
Tazarotene plus UVB phototherapy in the treatment of psoriasis. [2000.11]
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. [2000.10]
Photodamage pilot study: a double-blind, vehicle-controlled study to assess the efficacy and safety of tazarotene 0.1% gel. [2000.10]
Strategies to optimize efficacy, duration of remission, and safety in the treatment of plaque psoriasis by using tazarotene in combination with a corticosteroid. [2000.08]
Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. [2000.03]
Interactions between tazarotene and ultraviolet light. [1999.12]
Effect of topical tazarotene in the treatment of congenital ichthyoses. [1999.10]
[Tazarotene increases the antipsoriatic effect of dithranol in chronic psoriasis] [1999.10]
Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. [1999.06]
Combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. [1999.04]
Optimizing therapy: tazarotene in combination with phototherapy. [1999.04]
Tazarotene 0.1% gel in combination with mometasone furoate cream in plaque psoriasis: a photographic tracking study. [1999.01]
Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaque psoriasis. [1998.10]
Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. [1998.05]
The safety and efficacy of tazarotene gel, a topical acetylenic retinoid, in the treatment of psoriasis. [1998.01]
Well-designed clinical trials possibly related to Avage (Tazarotene)
Adapalene 0.1% and benzoyl peroxide 2.5% as a fixed-dose combination gel is as well tolerated as the individual components alone in terms of cumulative irritancy. [2008.09]
Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies. [2006.09]
Facial tolerability of topical retinoid therapy. [2004.11]
Instrumental evaluation of retinoid-induced skin irritation. [2002.05]
Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. [2001.06]
The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. [1999.04]
Other research related to Avage (Tazarotene)
Clindamycin phosphate 1.2%-benzoyl peroxide (5% or 2.5%) plus tazarotene cream
0.1% for the treatment of acne. [2013]
Cumulative irritation potential and contact sensitization potential of tazarotene
foam 0.1% in 2 phase 1 patch studies. [2012]
A randomized trial of the off-label use of imiquimod, 5%, cream with vs without
tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by
conservative staged excisions. [2012]
Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. [2011.07]
Efficacy and safety study of tazarotene cream 0.1% for the treatment of brittle nail syndrome. [2011.02]
Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: an observer-blinded randomized controlled study. [2011.01]
Clinical evidence for the role of a topical anti-inflammatory agent in comedonal
acne: findings from a randomized study of dapsone gel 5% in combination with
tazarotene cream 0.1% in patients with acne vulgaris. [2011]
Topical tazarotene cream (0.1%) in the treatment of facial acne: an open clinical trial. [2010.08]
Topical tazarotene vs. coal tar in stable plaque psoriasis. [2010.07]
Rapid improvement in digital ischemia and acral contracture in a collodion baby treated with topical tazarotene. [2010.06]
Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and
adapalene 0.3% gel in the treatment of patients with at least moderate facial
acne vulgaris. [2010]
Mimicry illuminating pitfalls in histopathologic diagnosis: nutritional deficiency-like dermatitis secondary to topical tazarotene and keratoacanthomatous pseudocarcinomatous hyperplasia in CD30+ lymphoproliferative disorder as illustrative. [2009.02]
Efficacy and safety of topical tazarotene: a review. [2009.02]
Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. [2008.09]
Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. [2008.06]
Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. [2008.06]
Response of juvenile circumscribed pityriasis rubra pilaris to topical tazarotene treatment. [2008.01]
A review of tazarotene in the treatment of photodamaged skin. [2008]
Childhood nail psoriasis: a useful treatment with tazarotene 0.05%. [2007.05]
Other possibly related research studies
Is switching retinoids a sound strategy for the treatment of acne vulgaris? [2008.06]
Treatment of lentigo maligna with imiquimod before staged excision. [2008.02]
[Topical corticosteroids and corticosteroid sparing therapy in psoriasis management] [2007.09]
A case report of Hailey-Hailey disease treated with alefacept (Amevive). [2008.02]
Treatment of locally metastatic melanoma: a novel approach. [2007.08]
Effects of topically applied acitretin in reconstructed human epidermis and the rhino mouse. [2008.01]
Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. [2007.07]
Pharmacological treatments for Basal cell carcinoma. [2007]
Palliative treatment of fingernail lichen planus. [2007.02]
New lesions on the knees with palmoplantar keratoderma. [2007.01]
Multiple keratoacanthomas in a young woman: report of a case emphasizing medical management and a review of the spectrum of multiple keratoacanthomas. [2007.01]
Cosmeceuticals: focus on topical retinoids in photoaging. [2008.11]
Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. [2008.05]
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. [2008.11]
[Update of the topical treatment of psoriasis] [2009.04]
[Topical treatments for psoriasis in 2009] [2009.04.22]
Topical treatments for chronic plaque psoriasis. [2009.04.15]
Changing the face of acne therapy. [2009.02]
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. [2009.04]
Psoriasis disappearance after the first phase of an oncologic treatment: a serendipity case report. [2008.11]
Topical retinoids in acne vulgaris: update on efficacy and safety. [2008]
Topical retinoids in acne--an evidence-based overview. [2008.12]
[Acting mechanism of longbixliao capsule on human prostatic stromal cells cultured in vitro] [2009.01]
Topical treatments for chronic plaque psoriasis. [2010.03.01]
[Narrow-band UVB therapy in psoriasis vulgaris: good practice guideline and recommendations of the French Society of Photodermatology] [2010.01]
New and experimental skin-directed therapies for cutaneous lymphomas. [2009]
Practice of phototherapy in the treatment of moderate-to-severe psoriasis. [2009]
Effect of retinoid pretreatment on outcomes of patients treated by photodynamic therapy for actinic keratosis of the hand and forearm. [2011.10.01]
|
